| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $4,499,408 ) |
| | 2026 | 2026 | HOLOBIOME, INC | 650 ALBANY ST STE 127 | BOSTON | MA | 02118-2518 | SUFFOLK | USA | AY2AX000171 | GUT-FEELINGS: Using Citizen Science for Large-Scale Microbiome Clinical Trials for Precision Mental Health in Adults | 000 | 1 | NIH | 3/9/2026 | $4,499,408 |
|
| Issue Date FY: 2024 ( Subtotal = -$2,792 ) |
| | 2024 | 2021 | HOLOBIOME INC | 650 ALBANY ST | BOSTON | MA | 02118-2518 | SUFFOLK | USA | R34NS126030 | Profiling the human gut microbiome for potential analgesic bacterial therapies | 000 | 1 | NIH | 2/12/2024 | -$2,792 |
| | 2024 | 2021 | HOLOBIOME INC | 650 ALBANY ST | BOSTON | MA | 02118-2518 | SUFFOLK | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 001 | 3 | NIH | 3/27/2024 | $0 |
| | 2024 | 2019 | HOLOBIOME INC | 650 ALBANY ST | BOSTON | MA | 02118-2518 | SUFFOLK | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 000 | 1 | NIH | 3/7/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | HOLOBIOME INC | 650 ALBANY ST | BOSTON | MA | 02118-2518 | SUFFOLK | USA | R43DK127864 | Development of a therapeutic bacterial consortium for constipation | 000 | 1 | NIH | 12/9/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R34NS126030 | Profiling the human gut microbiome for potential analgesic bacterial therapies | 001 | 1 | NIH | 8/24/2022 | $0 |
| | 2022 | 2021 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R34NS126030 | Profiling the human gut microbiome for potential analgesic bacterial therapies | 000 | 1 | NIH | 3/4/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,413,618 ) |
| | 2021 | 2021 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 000 | 3 | NIH | 6/10/2021 | $667,602 |
| | 2021 | 2021 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R34NS126030 | Profiling the human gut microbiome for potential analgesic bacterial therapies | 000 | 1 | NIH | 9/22/2021 | $1,446,416 |
| | 2021 | 2021 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R43DK127864 | Development of a therapeutic bacterial consortium for constipation | 000 | 1 | NIH | 7/5/2021 | $299,600 |
|
| Issue Date FY: 2020 ( Subtotal = $664,418 ) |
| | 2020 | 2020 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 001 | 2 | NIH | 5/5/2020 | $664,418 |
| | 2020 | 2020 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 003 | 2 | NIH | 5/12/2020 | $664,418 |
| | 2020 | 2020 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 002 | 2 | NIH | 5/8/2020 | -$664,418 |
| | 2020 | 2019 | HOLOBIOME, INC. | 1 KENDALL SQ STE B2001 | CAMBRIDGE | MA | 02139-1593 | MIDDLESEX | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 000 | 1 | NIH | 2/11/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $299,717 ) |
| | 2019 | 2019 | HOLOBIOME, INC. | 97 F ST | BOSTON | MA | 02127-2656 | SUFFOLK | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 001 | 1 | NIH | 6/25/2019 | -$299,717 |
| | 2019 | 2019 | HOLOBIOME, INC. | 97 F ST | BOSTON | MA | 02127-2656 | SUFFOLK | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 000 | 1 | NIH | 5/29/2019 | $299,717 |
| | 2019 | 2019 | HOLOBIOME, INC. | 97 F ST | BOSTON | MA | 02127-2656 | SUFFOLK | USA | R44DK120181 | Development of therapeutic GABA-producing bacteria | 002 | 1 | NIH | 7/2/2019 | $299,717 |
|
|
